OverviewSuggest Edit

Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products. It focuses on oncology and hematology, cardiovascular, inflammation, bone health, and neuroscience diseases. Its major brands include:

TypePublic
Founded1980
HQThousand Oaks, CA, US
Websiteamgen.com
Employee Ratings4
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)23,400(+9%)
Revenue (FY, 2020)$25.4 B(+9%)
Share Price (Feb 2021)$227.5 (-1%)
Cybersecurity ratingBMore

Key People/Management at Amgen

Robert A. Bradway

Robert A. Bradway

Chairman and Chief Executive Officer
Christophe Bourdon

Christophe Bourdon

Senior Vice President, General Manager, U.S. Oncology Business
Victoria H. Blatter

Victoria H. Blatter

Senior Vice President, U.S. Government Affairs
Judy Gawlik Brown

Judy Gawlik Brown

Senior Vice President, Corporate Affairs
Tia Bush

Tia Bush

Senior Vice President, Quality
Raymond Deshaies

Raymond Deshaies

Senior Vice President, Global Research
Show more

Amgen Office Locations

Amgen has offices in Thousand Oaks, Cambridge, Louisville, South San Francisco and in 56 other locations
Thousand Oaks, CA, US (HQ)
1 Amgen Center Dr
Cambridge, MA, US
360 Binney St
Louisville, KY, US
12000 Plantside Dr
South San Francisco, CA, US
1120 Veterans Blvd
Tampa, FL, US
2202 N Westshore Blvd
Washington, DC, US
601 13th St NW 12th Floor
Show all (65)

Amgen Financials and Metrics

Amgen Revenue

Embed Graph
View revenue for all periods
Amgen's revenue was reported to be $25.42 b in FY, 2020
USD

Revenue (FY, 2020)

25.4b

Gross profit (FY, 2020)

19.3b

Gross profit margin (FY, 2020), %

75.8%

Net income (FY, 2020)

7.3b

EBIT (FY, 2020)

9.1b

Market capitalization (25-Feb-2021)

131.4b

Closing stock price (25-Feb-2021)

227.5

Cash (31-Dec-2020)

6.3b

EV

158.1b
Amgen's current market capitalization is $131.4 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

23.0b22.8b23.7b23.4b25.4b

Revenue growth, %

6%(1%)4%(2%)

Cost of goods sold

4.2b4.1b4.1b4.4b6.2b

Gross profit

18.8b18.8b19.6b19.0b19.3b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.5b5.8b5.8b5.6b6.1b5.9b5.6b5.9b5.7b6.2b6.2b6.4b

Cost of goods sold

996.0m1.0b990.0m944.0m1.0b1.0b1.1b1.0b1.0b1.5b1.5b1.6b

Gross profit

4.5b4.8b4.8b4.6b5.0b4.9b4.5b4.9b4.7b4.6b4.7b4.9b

Gross profit Margin, %

82%82%83%83%83%82%81%83%82%75%76%76%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

3.2b3.8b6.9b6.0b6.3b

Accounts Receivable

3.2b3.2b3.6b4.1b4.5b

Inventories

2.7b2.8b2.9b3.6b3.9b

Current Assets

46.0b49.5b37.6b18.4b21.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

3.4b2.6b3.0b9.7b10.1b12.0b7.4b5.5b11.4b7.7b9.1b9.1b

Accounts Receivable

3.2b3.6b3.4b3.6b3.5b3.4b3.8b3.8b3.6b5.0b5.4b4.1b

Inventories

2.9b3.0b2.9b3.0b3.1b3.0b3.0b3.2b3.2b3.7b3.8b3.9b

Current Assets

46.5b48.4b49.8b40.7b38.0b38.3b35.2b30.7b31.1b18.8b22.9b22.7b
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

7.7b2.0b8.4b7.8b7.3b

Depreciation and Amortization

2.1b2.0b1.9b2.2b3.6b

Inventories

(80.0m)133.0m(3.0m)(66.0m)(215.0m)

Accounts Payable

(44.0m)424.0m(143.0m)164.0m45.0m
USDFY, 2016

Revenue/Employee

1.2m

Debt/Equity

1.2 x

Debt/Assets

0.4 x

Financial Leverage

2.6 x
Show all financial metrics

Amgen Operating Metrics

Feb, 2016FY, 2016Feb, 2017FY, 2017Feb, 2018FY, 2018Feb, 2019FY, 2019Feb, 2020

Countries

100 100 100 100

Facilities

190 180 190 190

Patents (US)

22 22 27 34

Phase III Trials Products

15 12 15 11 13 7 8 10 14
Show all operating metrics

Amgen Acquisitions / Subsidiaries

Company NameDateDeal Size
OtezlaNovember 19, 2019$13.40 b
NuevolutionMay 22, 2019
CatherexDecember 21, 2015
Dezima PharmaSeptember 16, 2015$300 m
Onyx PharmaceuticalsAugust 24, 2013$10.50 b
DeCODE GeneticsDecember 10, 2012$415 m
MN PharmaceuticalsApril 26, 2012$700 m
KAI PharmaceuticalsApril 10, 2012$315 m
MicrometJanuary 26, 2012
BergamoApril 08, 2011
Show more

Amgen Revenue Breakdown

Embed Graph

Amgen revenue breakdown by business segment: 22.4% from Enbrel, 13.8% from Neulasta, 11.4% from Prolia, 8.3% from XGEVA, 7.4% from Aranesp, 21.2% from Other products and 15.5% from Other

Amgen revenue breakdown by geographic segment: 25.5% from Rest of World and 74.5% from United States

Human Capital Metrics

Embed Graph
Show all human capital metrics

Amgen Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Amgen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Amgen Online and Social Media Presence

Embed Graph

Amgen Company Culture

  • Overall Culture

    F

    43/100

  • CEO Rating

    F

    55/100

  • Compensation

    F

    10/100

Learn more on Comparably

Amgen News and Updates

Insights on the BCL-2 (B Cell Lymphoma 2) Inhibitors Global Market to 2025 - Players Include Abbvie, Amgen and Novartis Among Others

Dublin, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The "Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering.

Worldwide BiTE Antibodies Industry to 2025 - Players Include Amgen, Bayers & Micromet Among Others

Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Global BiTE Antibodies Market , Price, Sales & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering.

Europe Cell and Gene Therapy Market Report 2021-2026: Prominent Players are Novartis, Spark Therapeutics, Amgen, Gilead Sciences & Organogenesis

Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Europe Cell and Gene Thera…

Amgen Drug Shrank 37% of Lung Cancer Tumors in Study

Amgen Drug Shrunk 37% of Lung Cancer Tumors in Study

World Autoinjectors Markets Report 2020-2027 Featuring Key Players - Amgen, Antares Pharma, Becton Dickinson and Co, Eli Lilly and Co, J&J, Mylan Novartis SHL Medical Teva Pharma & Ypsomed

DUBLIN, Jan. 22, 2021 /PRNewswire/ -- The "Autoinjectors Market by Type, Application, and End user: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global autoinjectors market was valued at $ 1,509.0 million in...

Worldwide Oncology Biosimilars Industry to 2026 - Featuring Biocon, Amgen and Sandoz International Among Others

Dublin, Jan. 18, 2021 (GLOBE NEWSWIRE) -- The "Oncology Biosimilars Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering. The report on the global oncology biosimilars market provides qualitative and quantitat…
Show more

Amgen Frequently Asked Questions

  • When was Amgen founded?

    Amgen was founded in 1980.

  • Who are Amgen key executives?

    Amgen's key executives are Robert A. Bradway, Christophe Bourdon and Victoria H. Blatter.

  • How many employees does Amgen have?

    Amgen has 23,400 employees.

  • What is Amgen revenue?

    Latest Amgen annual revenue is $25.4 b.

  • What is Amgen revenue per employee?

    Latest Amgen revenue per employee is $1.1 m.

  • Who are Amgen competitors?

    Competitors of Amgen include Viatris, Allergan and Novo Nordisk.

  • Where is Amgen headquarters?

    Amgen headquarters is located at 1 Amgen Center Dr, Thousand Oaks.

  • Where are Amgen offices?

    Amgen has offices in Thousand Oaks, Cambridge, Louisville, South San Francisco and in 56 other locations.

  • How many offices does Amgen have?

    Amgen has 65 offices.